CYTK vs. RNA, CNST, ZGNX, ICPT, ORIC, TEVA, GMAB, RPRX, BMRN, and BGNE
Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Avidity Biosciences (RNA), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Intercept Pharmaceuticals (ICPT), ORIC Pharmaceuticals (ORIC), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE).
Cytokinetics (NASDAQ:CYTK) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Cytokinetics and Cytokinetics both had 11 articles in the media. Cytokinetics' average media sentiment score of 0.86 beat Avidity Biosciences' score of 0.46 indicating that Cytokinetics is being referred to more favorably in the media.
Avidity Biosciences has a net margin of -2,103.78% compared to Cytokinetics' net margin of -14,141.74%. Cytokinetics' return on equity of 0.00% beat Avidity Biosciences' return on equity.
Cytokinetics received 643 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 79.35% of users gave Cytokinetics an outperform vote while only 65.28% of users gave Avidity Biosciences an outperform vote.
Avidity Biosciences has higher revenue and earnings than Cytokinetics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Cytokinetics presently has a consensus price target of $77.06, indicating a potential upside of 29.10%. Avidity Biosciences has a consensus price target of $44.29, indicating a potential downside of 8.01%. Given Cytokinetics' higher probable upside, analysts clearly believe Cytokinetics is more favorable than Avidity Biosciences.
Cytokinetics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Summary
Cytokinetics beats Avidity Biosciences on 8 of the 15 factors compared between the two stocks.
Get Cytokinetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytokinetics Competitors List
Related Companies and Tools
